CU20220023A7 - Derivados de 2-azaspiro[3,4]octano como agonistas de m4 - Google Patents

Derivados de 2-azaspiro[3,4]octano como agonistas de m4

Info

Publication number
CU20220023A7
CU20220023A7 CU2022000023A CU20220023A CU20220023A7 CU 20220023 A7 CU20220023 A7 CU 20220023A7 CU 2022000023 A CU2022000023 A CU 2022000023A CU 20220023 A CU20220023 A CU 20220023A CU 20220023 A7 CU20220023 A7 CU 20220023A7
Authority
CU
Cuba
Prior art keywords
agonists
azaspiro
octane derivatives
formula
octane
Prior art date
Application number
CU2022000023A
Other languages
English (en)
Inventor
Amy Calhoun
Xin Chen
Kevin Matthew Gardinier
Edward Charles Hall
Keith Jendza
Nancy Labbe-Giguere
James Neef
Daniel Steven Palacios
Ming Qian
Michael David Shultz
Christopher G Thomson
Kate Yaping Wang
Fan Yang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20220023A7 publication Critical patent/CU20220023A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

<p>En la presente se proporcionan compuestos de acuerdo con la Fórmula (I)</p> <p> </p> <p>ESPACIO PARA FÓRMULA</p> <p> </p> <p>o una sal farmacéuticamente aceptable de los mismos, en donde R1, R2, R3, R5, y R7 se definen en la presente. También se proporcionan en la presente composiciones farmacéuticas que comprenden un compuesto de Fórmula (I) así como el uso de dichos compuestos como agonistas del receptor M4.</p>
CU2022000023A 2019-10-09 2020-10-07 Derivados de 2-azaspiro[3,4]octano como agonistas de m4 CU20220023A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962912980P 2019-10-09 2019-10-09
PCT/IB2020/059430 WO2021070090A1 (en) 2019-10-09 2020-10-07 2-azaspiro[3.4]octane derivatives as m4 agonists

Publications (1)

Publication Number Publication Date
CU20220023A7 true CU20220023A7 (es) 2022-11-07

Family

ID=72944205

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2022000023A CU20220023A7 (es) 2019-10-09 2020-10-07 Derivados de 2-azaspiro[3,4]octano como agonistas de m4

Country Status (21)

Country Link
US (2) US11548865B2 (es)
EP (1) EP4041389A1 (es)
JP (1) JP7349570B2 (es)
KR (1) KR20220079921A (es)
CN (1) CN114555592A (es)
AR (1) AR120170A1 (es)
AU (1) AU2020361735B2 (es)
CA (1) CA3156320A1 (es)
CL (1) CL2022000893A1 (es)
CO (1) CO2022004341A2 (es)
CR (1) CR20220141A (es)
CU (1) CU20220023A7 (es)
EC (1) ECSP22027287A (es)
IL (1) IL291316A (es)
JO (1) JOP20220082A1 (es)
MX (1) MX2022004213A (es)
PE (1) PE20221453A1 (es)
TW (1) TW202128649A (es)
UY (1) UY38906A (es)
WO (1) WO2021070090A1 (es)
ZA (1) ZA202202912B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20221453A1 (es) * 2019-10-09 2022-09-21 Novartis Ag Derivados de 2-azaspiro[3,4]octano como agonistas de m4
WO2024059249A1 (en) * 2022-09-16 2024-03-21 Cerevel Therapeutics, Llc M4 activators/modulators and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276520A1 (en) 2002-11-13 2006-12-07 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
WO2006006490A1 (ja) 2004-07-08 2006-01-19 Ono Pharmaceutical Co., Ltd. スピロ化合物
US7880007B2 (en) * 2004-11-29 2011-02-01 Vertex Pharmaceuticals Incorporated Bicyclic substituted phenyl piperidine modulators of muscarinic receptors
JP5420408B2 (ja) 2006-08-25 2014-02-19 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１型のインヒビター
AU2009309988A1 (en) 2008-10-29 2010-05-06 Grunenthal Gmbh Substituted spiroamines
CN102361876B (zh) 2009-01-26 2015-02-04 以色列生物研究所 二环杂环螺环化合物
EP2675812B1 (en) 2011-02-18 2017-08-30 Vertex Pharmaceuticals Incorporated Chroman - spirocyclic piperidine amides as modulators of ion channels
JP6062432B2 (ja) 2011-07-27 2017-01-18 ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． プロテインキナーゼ阻害薬用スピロ環状分子
WO2014039489A1 (en) 2012-09-07 2014-03-13 Zoetis Llc Spirocyclic derivatives as antiparasitic agents
DK2897948T3 (en) * 2012-09-18 2016-12-05 Heptares Therapeutics Ltd BICYCLIC AZA RELATIONS AS MUSCARIN M1 RECEPTOR AGONISTS
JP6479029B2 (ja) * 2014-02-06 2019-03-06 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
CN107108597B (zh) 2014-10-31 2020-04-17 英立维尔英国有限公司 多巴胺d3受体拮抗剂化合物
GB201504675D0 (en) * 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
BR122024002146A2 (pt) 2016-06-10 2024-03-05 Vitae Pharmaceuticals, Inc. Compostos inibidores da interação de menina-llm e forma cristalina destes
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
CN108456208B (zh) 2017-02-22 2021-04-16 广州市恒诺康医药科技有限公司 氮杂螺环类化合物及其制备方法和应用
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
GB201709652D0 (en) 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
EP4219464A1 (en) 2018-03-23 2023-08-02 Pfizer Inc. Piperazine azaspiro derivaves
GB201810245D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
PE20221453A1 (es) * 2019-10-09 2022-09-21 Novartis Ag Derivados de 2-azaspiro[3,4]octano como agonistas de m4
WO2021070091A1 (en) * 2019-10-09 2021-04-15 Novartis Ag 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists

Also Published As

Publication number Publication date
KR20220079921A (ko) 2022-06-14
AR120170A1 (es) 2022-02-02
AU2020361735B2 (en) 2024-04-18
CO2022004341A2 (es) 2022-04-29
US20210107889A1 (en) 2021-04-15
UY38906A (es) 2021-05-31
IL291316A (en) 2022-05-01
JP2022552244A (ja) 2022-12-15
MX2022004213A (es) 2022-05-03
AU2020361735A1 (en) 2022-04-21
EP4041389A1 (en) 2022-08-17
JP7349570B2 (ja) 2023-09-22
ZA202202912B (en) 2023-04-26
CA3156320A1 (en) 2021-04-15
JOP20220082A1 (ar) 2023-01-30
CL2022000893A1 (es) 2023-01-20
PE20221453A1 (es) 2022-09-21
TW202128649A (zh) 2021-08-01
US20230212139A1 (en) 2023-07-06
WO2021070090A1 (en) 2021-04-15
US11548865B2 (en) 2023-01-10
CR20220141A (es) 2022-05-03
ECSP22027287A (es) 2022-12-30
CN114555592A (zh) 2022-05-27

Similar Documents

Publication Publication Date Title
UY38297A (es) Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
CO2021015698A2 (es) Moduladores de thr-β y métodos de uso de estos
CL2022001392A1 (es) Compuestos tricíclicos sustituidos
BR112022012641A2 (pt) Compostos tricíclicos substituídos
AR050407A1 (es) Compuestos quinolinon-carboxamida como agonistas del receptor 5-ht4. procesos de obtencion y composiciones farmaceuticas
CO2017009891A2 (es) Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta)
AR117814A1 (es) Compuestos moduladores de fxr (nr1h4)
NI201400031A (es) Derivados de ( 4 - fenilimidazol - 2 - il ) etilamina útiles como moduladores de canal de sodio
CL2022000893A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
ECSP22027784A (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
CL2020001817A1 (es) Moduladores del receptor c5a
CL2020002188A1 (es) Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmacéutico.
PE20201148A1 (es) Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
AR127254A1 (es) Ciertas octahidrofuro[3,4-b]pirazinas como moduladores del receptor de glp-1
UY39625A (es) Derivados tricíclicos útiles como inhibidores de parp7
AR107310A1 (es) Inhibidores de tetrahidrocarbazol de receptores sirt1
AR119317A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
BR112022006157A2 (pt) Derivados de 5-oxa-2-azaespiro[3.4]octano como agonistas de m4
AR124698A1 (es) Derivados tricíclicos útiles como inhibidores de parp7
BR112022006386A2 (pt) Derivados de 2-azaspiro[3.4]octano como agonistas de m4
AR116080A1 (es) Derivados de 1-imidazotiadiazol-2h-pirrol-5-ona
AR116966A1 (es) Inhibidores de quinasa dependiente de ciclina 7 (cdk7)
ECSP23075535A (es) Compuestos cíclicos y métodos de uso